Centrally Acting Analgesics versus SSRIs in Osteoarthritis: Study Sheds Light on Joint Outcomes and Role of Comorbid Depression
USA: The choice of second-line therapy for patients with osteoarthritis (OA) who experience inadequate pain relief from standard anti-inflammatory medications has critical implications for long-term joint survival.
Emerging data indicate that initiating centrally acting analgesics (CAAs)—such as gabapentinoids, tricyclic antidepressants, or serotonin-norepinephrine reuptake inhibitors (SNRIs)—is associated with a significantly higher long-term risk of total joint arthroplasty compared to initiating selective serotonin reuptake inhibitors (SSRIs). This divergence suggests that the clinical management of comorbid depression may play a far more influential role in mitigating OA symptom progression and avoiding surgical interventions than the benefits derived from central pain-masking effects alone.
The findings are from a large population-based cohort study published in BMC Medicine, led by Zhiqiang Wang and colleagues, which examined real-world treatment patterns and long-term surgical outcomes in patients with osteoarthritis. Using data from the IQVIA Medical Record Database, the researchers focused on adults aged 40 to 89 years diagnosed with OA who initiated either CAAs or SSRIs as part of routine clinical care.
A new-user, active comparator design was applied, and patients were propensity score–matched in a 1:1 ratio to ensure balanced baseline characteristics. The final analysis included 11,734 CAA initiators and an equal number of SSRI initiators, followed over time to assess the risk of total knee or hip arthroplasty. Cox proportional hazards models were used to estimate risk, with additional analyses accounting for the competing risk of death and treatment discontinuation.
The following were the key findings:
- Patients treated with centrally acting analgesics showed a consistently higher risk of joint replacement compared with those receiving SSRIs.
- In the primary analysis, centrally acting analgesic users had an 81% higher risk of total joint arthroplasty than SSRI users.
- After adjustment for confounding factors and competing risks, the increased risk remained significant, although the magnitude was slightly reduced.
- Patients receiving SSRIs were associated with comparatively better long-term joint outcomes.
- In subgroup analyses of patients with both osteoarthritis and depression, the same trend was observed, but the association was not statistically significant.
These findings prompt a re-evaluation of centrally acting analgesics in osteoarthritis care. While effective for pain control, CAAs may not prevent disease progression and are linked to higher joint replacement risk. In contrast, SSRIs may offer broader benefits affecting pain, activity, and disease course.
Despite robust adjustments, residual confounding cannot be excluded given the observational design, though the large real-world dataset strengthens the evidence.
Overall, treatment choice in osteoarthritis may influence long-term surgical outcomes beyond symptom relief, highlighting the need for further research into underlying mechanisms and the potential protective role of mood-targeted therapies.
Reference:
Wang, Z., Westerland, M., Peloquin, C. et al. Associations of centrally acting analgesic use with total joint arthroplasty compared to selective serotonin reuptake inhibitor among osteoarthritis patients in a large prospective cohort. BMC Med (2026). https://doi.org/10.1186/s12916-026-04917-6
Next Story